| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698050 | Clinical Oncology | 2017 | 7 Pages |
Abstract
The stability of health utility scores and problems reported by patients undergoing treatment indicate that SBRT for liver metastases does not impart a significant adverse effect on quality of life. These results may be used for future economic evaluation of SBRT.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
B. Warren, P. Munoz-Schuffenegger, K.K.W. Chan, W. Chu, J. Helou, D. Erler, H. Chung,